Study on the Role of FDG-PET in Patients With FL at Time of Relapse/Progression

Study on the Role of FDG-PET in Patients With Follicular Lymphoma at Time of Relapse/Progression

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT03525665

Enrollment

175

Registered

2018-05-16

Start date

2016-05-31

Completion date

2019-12-30

Last updated

2020-02-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Follicular Lymphoma

Keywords

Follicular lymphoma, FDG-PET, Relapse/progression

Brief summary

The study is designed as a retrospective analysis of patients with relapsed/refractory FL identified by the hematological centers of Italy.

Detailed description

The study does not require any intervention on the patient, but it involves the simple collection of data that are already present in the medical record. Since this is a retrospective study, it will not require further analysis or diagnostic investigations than those already made.

Interventions

OTHERMetabolic activity measured by FDG-PET

To evaluate whether metabolic activity measured by FDG-PET (SUV max) at time of relapse is predictive of patient's outcome.

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Patients with initial diagnosis of follicular lymphoma since 2001 * Histological confirmation of follicular lymphoma, grade I, II, III according to WHO 2008 classification, at the time of initial diagnosis * Systemic first-line treatment with immuno-chemotherapy * PET availability at the time of response after first-line treatment (optional) * Clinical and radiological evidence of FL relapse or progression * Histological confirmation of relapse (strongly recommended) * PET availability of at the time of relapse/progression and images available for central assessment * Availability of clinical, laboratory and therapeutic treatment data at the time of initial diagnosis and relapse/progression * Follow up of at least 12 months after relapse/progression

Exclusion criteria

* None

Design outcomes

Primary

Measure	Time frame	Description
PFS	24 months	Progression free survival from time of relapse/progression

Secondary

Measure	Time frame	Description
OS	24 months	Overall survival

Countries

Italy

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026